The company also has operations in Chile and Iceland © Benchmark
Novo acquired the company earlier this year in a deal worth up to £260 million and, according to Benchmark, the new regime will allow it to focus on:
- Optimising and strengthening its existing salmon and shrimp breeding programmes.
- Expanding strategically into new markets and species, harnessing the company’s expertise and technologies to enhance seafood production globally.
- Investing in production and nucleus facilities globally, including in Norway, Iceland and Chile – to enhance biosecurity, increase production capacity and secure supply.
- Building strategic partnerships, including with key customers, suppliers and R&D institutions.
- Expanding its provision of genetic and genotyping services to help realise the benefit of genetic improvement on the production of multiple species and markets.
- Science, innovation and technology translation in areas such as genomics, phenotyping, and reproductive biotechnology, including potential future gene editing solutions.
Novo Holdings’ life science portfolio spans more than 150 companies including Stingray Marine Solutions, another Norwegian company that drives innovation in the aquaculture industry.
“We believe in the power of genetics to transform aquaculture to improve animal welfare and make food production more sustainable,” said Geir Olav Melingen, CEO of Benchmark Genetics. “With Novo Holdings as our new owner, we will realise our mission to provide high-performing sustainable genetic solutions that bring value to aquaculture producers worldwide and more healthy food to the table of consumers.”
Benchmark Genetics has also gained full ownership of its state-of-the-art salmon breeding facility in Salten, Norway.
